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Abstract
Background: There is a dearth of instruments that have been developed and validated for use with children living
with HIV under the age of 17 years in the Kenyan context. We examined the psychometric properties and measurement invariance of a short version of the Berger HIV stigma scale administered to perinatally HIV-infected adolescents
in a rural setting on the Kenyan coast.
Methods: A cross-sectional study was conducted among 201 perinatally HIV-infected adolescents aged 12–17 years
between November 2017 and October 2018. A short version of the Berger HIV stigma scale (HSS-40) containing
twelve items (HSS-12) covering the four dimensions of stigma was evaluated. The psychometric assessment included
exploratory factor analysis, confirmatory factor analysis (CFA), and multi-group CFA. Additionally, scale reliability was
evaluated as internal consistency by calculating Cronbach’s alpha.
Results: Evaluation of the reliability and construct validity of the HSS-12 indicated insufficient reliability on three
of the four subscales. Consequently, Exploratory Factor Analysis (EFA) was conducted to identify problematic items
and determine ways to enhance the scale’s reliability. Based on the EFA results, two items were dropped. The Swahili
version of this new 10-item HIV stigma scale (HSS-10) demonstrated excellent internal consistency with a Cronbach
alpha of 0.86 (95% confidence interval (CI) 0.84–0.89). Confirmatory Factor Analysis indicated that a unidimensional
model best fitted the data. The HSS-10 presented a good fit (overall Comparative Fit Index = 0.976, Tucker Lewis
Index = 0.969, Root Mean Square Error of Approximation = 0.040, Standardised Root Mean Residual = 0.045). Additionally, multi-group CFA indicated measurement invariance across gender and age groups at the strict invariance level as
ΔCFI was ≤ 0.01.
Conclusion: Our findings indicate that the HSS-10 has good psychometric properties and is appropriate for evaluating HIV stigma among perinatally HIV-infected adolescents on the Kenyan coast. Further, study results support the
unidimensional model and measurement invariance across gender and age groups of the HSS-10 measure.
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Background
Globally, an estimated 1.7 million adolescents (10–
19 years) were living with the Human Immunodeficiency
Virus (HIV) in 2019, and almost 88% of them live in
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sub-Saharan Africa [1]. The improved access to antiretroviral therapy (ART), especially in resource-constrained
settings, has significantly boosted perinatally HIVinfected children’s survival. Subsequently, many of these
children have transitioned into adolescence and older age
groups [2, 3], although HIV-related challenges, such as
stigma, continue to negatively impact their well-being [4].
Erving Goffman [5] defines stigma as an attribute that
is deeply discrediting" and reduces a person "from a whole
and usual person to a tainted discounted one. Individuals
living with HIV experience stigma through three interrelated mechanisms: anticipated stigma, internalised
stigma, and enacted stigma [6]. Anticipated stigma refers
to the extent to which individuals living with HIV expect
to experience discrimination and prejudice from other
people in the future [7]. Internalised stigma refers to
the extent to which individuals living with HIV approve
of the negative feelings and beliefs associated with HIV/
AIDS about themselves [8]. Finally, enacted stigma refers
to the extent to which individuals living with HIV consider that they have experienced discrimination or prejudice from others in the community [9].
HIV is highly stigmatisable due to various reasons,
most being misperceptions. For instance, it is considered
contagious, severe, and resulting from norm violating
volitional behaviour such as commercial sex work, homosexuality, and promiscuity [10, 11]. Besides it being dehumanising, HIV stigma presents a significant impediment
to the adoption of HIV preventive behaviours such as voluntary disclosure of HIV status, HIV testing, and treatment adherence [6, 12] [13], thus causing a major setback
to efforts made in the prevention and treatment of HIV/
AIDs [14, 15]. Furthermore, the fact that adolescence is
marked with rapid physical and psychological changes,
coupled with unfamiliar demands amidst an increasing
level of independence [16], suggests that adolescents may
experience severe consequences arising from HIV stigma
[17]. Furthermore, studies have found that perceived HIV
stigma makes adolescents hide their status that needs
to be well guarded due to the fear of rejection, isolation,
and stigmatisation from others [17, 18]. Therefore, adolescents adopt either partial disclosure or non-disclosure
strategies to avoid negative social consequences [17]. All
these negatively impact both health-seeking behaviour
and health outcomes. Although the negative impacts of
stigma have been widely documented, the literature on
HIV stigma has been majorly skewed towards adults living with HIV ignoring the impacts of stigma on adolescents living with HIV [18].
Scales to measure HIV stigma among adults have
been developed and validated in high-income [19,
20] and lower-middle-income settings [21]. Berger’s
40-item HIV stigma scale [HSS-40] [19] is widely used
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as it captures the three stigma mechanisms (anticipated, internalised, enacted) for individuals living
with HIV, as suggested by Earnshaw and Chaudoir [6].
Berger’s 40-item HIV stigma scale was originally developed and used in the USA [19]. It is a reliable and valid
instrument for assessing HIV stigma among infected
adults [19]. Several versions of the (HSS-40) have
been adapted and used with children in Sweden [22]
and young adults with HIV in Thailand [23] and the
USA [24]. However, there is a lack of valid and reliable
stigma measures, especially in resource-limited settings
[25, 26]. Further, to our knowledge, there is a dearth of
instruments that have been developed and validated
for use with children living with HIV under the age of
17 years in the Kenyan context.
Research has shown that some of the lived experiences,
underlying mechanisms, and perceptions surrounding
stigma are similar among adolescents, young adults, and
adults living with HIV [17, 27]. This finding’s implication
is that stigma assessment tools or scales developed for
adults living with HIV may potentially be useful for adolescents. However, before using these measures widely,
the psychometric properties of these scales must be
adequately examined. Therefore, the 12-item HIV stigma
scale (HSS-12) version of the Berger HIV stigma scale
[20] was used in the present study. HSS-12 has comparable psychometric properties to the full-length scale, and
its brevity facilitates the inclusion of HIV stigma assessments into extensive surveys [20].
Given these knowledge gaps, the purpose of this quantitative study was to evaluate the psychometric characteristics (validity and reliability) and measurement
invariance of the short version of the Berger HIV stigma
scale to determine its usefulness for a longitudinal study
among perinatally HIV adolescents from a rural coastal
setting in Kilifi Kenya.

Methods
Study setting

The study setting’s details, participants, and recruitment
processes have been previously described in detail [28].
A cross-sectional study with perinatally HIV-infected
adolescents aged 12–17 years was conducted between
November 2017 and October 2018 at the Centre for Geographic Medicine Research-Coast at the Kenya Medical
Research Institute (CGMR-C/KEMRI). All participants
were residents of Kilifi County on the coast of Kenya.
Approximately 1.4 million people were Kilifi County residents by 2016, most (61%) residing in the rural areas [29].
Kilifi County is classified as a medium HIV county with a
prevalence of 4.5%, of whom 19% are young people aged
19–24 years [30].
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Participants

Data collection procedures

We have used baseline data for an ongoing longitudinal study, the Adolescent Health Outcomes Study
(AHOS). Two hundred and one (201) perinatally HIVinfected adolescents were enrolled and subsequently
interviewed. Study participants were adolescents aged
between 12 and 17 years at the time of recruitment,
with confirmed HIV-positive status. They needed to be
fully aware of their HIV status and that of their biological mother and provided written parental or guardian
consent and adolescents’ assent. All eligible adolescent participants had to be accompanied by a caretaker
during their appointment for data collection at the
CGMRC-KEMRI.

Study participants were recruited through sequential
sampling from all eligible and consenting families attending HIV clinics at eight health facilities in Kilifi County.
In addition, perinatally HIV-infected adolescents and
their caregivers were recruited by a trained research
assistant in liaison with health workers at participating
HIV treatment facilities.
A trained research assistant administered the Swahili version of the HIV stigma scale (HSS-12) to each
study participant (in person) in a quiet private study
clinic, using an android tablet. In addition, demographic
information such as age, sex, education level, orphanhood, and clinical characteristics such as HIV viral load
concentration and HIV clinical staging data were also
collected [32, 33]. The data were entered in REDCap electronic database hosted at the KEMRI Wellcome Trust
Programme. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed
to support data capture for research studies, providing
(1) an intuitive interface for validated data capture; (2)
audit trails for tracking data manipulation and export
procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and
(4) procedures for data integration and interoperability
with external sources.

Measures
HIV stigma

We adopted the 12-item HIV stigma scale (HSS-12)
version of the Berger HIV stigma scale to assess the
perceived stigma felt by perinatally HIV-infected adolescents. This tool was selected because of its confirmed
comparable psychometric properties (reliability and
validity) to the full-length scale, albeit short and simple
[20]. The questionnaire has twelve items (see Table 2)
categorised under four dimensions of stigma: (1) personalised stigma, perceived stigmatising consequences
of others knowledge of an individual’s HIV status; (2)
disclosure concerns, fear of self-disclosure, and fear that
those who know would tell others; (3) concerns with public attitudes, conceptions of people about a person with
HIV; and (4) negative self-image, experiencing oneself
as infected and not as good as others each comprising a
subscale of the instrument [22]. The 12 items are statements that a person living with HIV can agree or disagree with on a Likert scale rated as 1 “strongly disagree,”
2 “disagree,” 3 “agree,” and 4 “strongly agree.” Possible
scores per item range from 1 to 4 (3–12 for sub-scale),
and a total score ranging between (12 and 48) is derived
from the summation of item scores. Higher scores indicate a higher level of perceived HIV stigma.
Instrument translation

The HSS-12 was forward translated into Swahili by
research team members fluent in English and Swahili and
then back-translated into English by an independent back
translator not involved in the project. The back-translated version of the tool was checked for comparability
with the original English questionnaire [31]. In addition,
members of the research team had a harmonisation
meeting to review the questionnaire to ensure its cultural
relevance to the study sample.

Statistical analysis

Statistical analysis was performed for three psychometric properties of internal consistency, factor structure,
and measurement invariance. The internal consistency
was analysed using Cronbach’s alpha (α), whereby the
value of α was considered acceptable if ≥ 0.7 [34, 35]. The
factor structure was analysed using confirmatory factor
analysis (CFA) based on a four-factor structure of the
HSS-12. CFA was tested using weighted least squares
mean and variance (WLSMV) using Lavaan [36] package in R statistics [37]. The criteria for a model fit were
assessed using the chi-square test (χ2), Tucker-Lewis
Index (TLI), Comparative Fit Index (CFI), and root mean
square error of approximation (RMSEA). The criteria
for acceptable fit was insignificant χ2 tests, a root mean
square error of approximation (RMSEA) of < 0.05, a TLI,
and a CFI of ≥ 0.90 [38]. An Exploratory Factor Analysis (EFA) using the principal component analysis (PCA)
factor extraction method with oblimin rotation was carried out when the first CFA did not fit well. The Kaiser–
Meyer–Olkin measure of sampling adequacy (KMO) and
Bartlett’s test of sphericity were used to investigate data
adequacy for factor analysis. Factor extraction was based
on Kaiser’s criterion of retaining factors with eigenvalues
of > 1 and visual exploration of the scree plot for breaks
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or discontinuities in the graphical representation of the
eigenvalues [39]. We analysed the measurement invariance using the four CFA models with robust WLSMV
to account for the stigma indicators’ categorical nature
across age and sex. Specifically, we assessed the change
in CFI and the chi-square difference between the more
and least constrained models based on scaling correction
factors [40]. Measurement invariance was assumed when
a change in CFI was ≤ 0.01 and when the chi-square was
non-significant between successively more restricted
models [41]. Frequencies (percentages) and median (with
interquartile range [IQR]) were used to describe the sample characteristics. The confirmatory and exploratory
factor analyses were conducted using Lavaan, SemTools,
and Psych packages in R software version 4.0.2 [37]. All
other statistical analyses were conducted using Stata version 14.0 statistical software package [42]. For all analyses, p ≤ 0.05 was considered statistically significant for all
tests of the hypothesis.

Table 1 Participant’s
characteristics

Results

Perceived HIV-stigma scoreb—median (IQR)

Participants’ characteristics

Orphanhood

Participants’ socio-demographic characteristics are presented in Table 1. Overall, 201 perinatally HIV-infected
adolescents attending treatment and care clinics at health
facilities in Kilifi County were recruited and interviewed
between November 2017 and October 2018. Respondents had a median age of 13 years (IQR = 12–15) ranging from 12 to 17. The vast majority of the respondents
were in early adolescence [12–14 years] (69.7%). Slightly
more than half (52%) were females and orphaned (51.2%)
(either partial [a child with only one parent alive] or
total). Most study participants were in stage 2 of the
WHO clinical staging (77.2%). Perceived HIV stigma
score ranged from 12 to 48 with a median score of 15
(IQR: 12–20).
Analyses of the HSS‑12

A summary of the participant’s scores on the HSS-12 is
shown in Table 2. The median score was 3 (IQR: 1–5)
for the personalised stigma subscale, 6 (IQR: 4–7) for
the disclosure concern subscale, 3 (IQR: 1–5) for the
public attitude’s subscale, 3 (IQR: 2–5) for the negative
self-image subscale and 15 (IQR: 12–20) for the HSS12 stigma scale. Individual items had medians and IQR
ranging from 1 to 2 and 0 to 3, respectively.
Internal consistency and factor structure

The HSS-12 had an internal consistency reliability coefficient alpha = 0.83 (95% CI 0.79–0.87) (see Table 2).
Corrected item-total correlation coefficients, an indicator of internal construct validity, had a range between
0.17 and 0.95, indicating that the broadness of the

sociodemographic

Sample characteristics

and

clinical

Total sample
n

Sociodemographic characteristics

201

Age—years (12–17), median (IQR)

13 (12–15)

%

Sex
Female

105

52.2

Male

96

47.8

Adolescence stage
Early adolescence (12–14 years)

140

69.7

Mid-adolescence (15–17 years

61

30.3

Education (number of years in formal education)—mean (SD)

1.8(0.5)

Not attending school

2

Special school

1

1.0

Lower primary school (pre-primary—class 5)

100

50.5

Upper primary school (class 6–8)

81

40.9

Secondary school

14

7.1

0.5

15(12–20)

Both parents alive

98

48.8

Only mother alive

37

18.4

Only father alive

29

14.4

Both parents died

37

18.4

Clinical characteristics
HIV viral load concentration
≤ 1000 copies/mL

> 1000 copies/mL

WHO clinical stage, OM = 5

108

56.8

82

43.2

Stage 1

10

5.1

Stage 2

142

72.1

Stage 3

45

22.8

OM observation with missing value, SD standard deviation, a score range = 0–9,
b score range = 12–48, IQR interquartile range

intended stigma concept had been captured. Despite
the very good internal consistency for the full scale,
the reliability of three subscales was low: personalised
stigma α = 0.68 (95% CI; 0.58–0.77), disclosure concern
α = 0.44 (95% CI; 0.30–0.58), and concerns with public
attitudes α = 0.65 (95% CI; 0.55–0.76) sub-scales. Especially concerning was the extremely poor reliability of
the disclosure concern subscale.
Confirmatory Factor Analyses of the HSS-12 showed
a good fit with the original subscale structure. The χ2
test was statistically significant (χ2 = 75.804, df = 50,
p = 0.011) and other model fit indices indicated that
our data fit the four-factor model (RMSEA: 0.051; TLI:
0.933; CFI: 0.949). Although the model’s goodness of
fit was generally within the acceptable range, an EFA
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Table 2 Descriptive statistics for the short-form version (HSS-12) of the HIV Stigma Scale
Item

Median item Corrected
scorea (IQR) item
correlation

Personalised stigma
Some people stop touching me soon they
know/realise I am infected with HIV/AIDS

1 (0–2)

0.63

People I care for stopped calling me after
knowing I suffer from AIDs

1 (0–2)

0.67

I have lost friends for telling/explaining that I
have AIDS

1 (0–2)

0.62

Telling someone that I have AIDS is dangerous* 1 (0–2)

0.95

I do all I can to keep my AIDS (HIV) status secret 2 (1–3)

0.24

I am very careful to that person I tell about my
HIV status (I am cautious/very careful to (?of )
the people I tell my HIV status)

2 (2–3)

0.17

People who are suffering from AIDS are treated 1 (0–2)
as if they are not like the other people

0.63

People believe that a person infected with HIV
is dirty

1 (0–2)

0.66

Many people are worried when they are near a
person infected with HIV

1 (0–2)

0.60

I feel guilty because I am infected with HIV

1 (0–2)

0.64

People’s attitudes about HIV/AIDS makes me
feel very bad

1 (1–2)

0.66

I feel I am not as good as others because am
infected with HIV

1 (0–2)

0.68

Disclosure concerns

Concerns about public attitudes

Negative self image

Overall

Total subscale
scoreb [Median,
(IQR)]

Reliability
α

Validity construct

3 (1–5)

0.68 (95% CI; 0.58–0.77)

6 (4–7)

0.44 (95% CI; 0.30–0.58)

3 (1–5)

0.65 (95% CI; 0.55–0.76)

3 (2–5)

0.70 (95% CI; 0.61–0.79)

15 (12–20)

0.83 (95% CI; 0.79–0.87) 0.949 0.051

CFI

RMSEA TLI

0.933

IQR interquartile range
a

Possible score for each item 1–4; higher scores reflect a higher level of perceived HIV stigma

b

Possible score 3–12 on each scale; higher scores reflect a higher level of perceived HIV-related stigma

was conducted to abridge the scale and create a better
model.
Exploratory factor analysis: creation of a new HSS model

We performed a parallel analysis (maximum likelihood)
using a polychoric correlation matrix which suggested
that the HSS-12 had only one factor with an eigenvalue > 1.0 (see Fig. 1), which accounted for 33.0% of the
variance. Consequently, we conducted an exploratory
factor analysis to clarify the HSS-12 structure. We examined factor loadings from the resultant EFA and dropped
items with factor loadings of 0.4 or lower. Two items
assessing “I do all I can to keep my AIDS (HIV) status
secret” and “I am very careful to that person I tell about
my HIV status” were dropped from the disclosure concern subscale due to low factor loadings. Factor analysis
(oblimin rotation) revealed a unidimensional scale consisting of 10 items (see Fig. 2 for the factor loadings of the

Fig. 1 Scree plot showing eigenvalues from parallel analysis of the
HSS-12

HSS-10 item abridged scale). Thus, the dropping of the
two items improved scale reliability from 0.83 to 0.86.
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People avoid touching me if they know I
have HIV

People I care about stopped calling after
learning I have HIV

0.60

I have lost friends by telling them I have
HIV

0.63
0.59

Telling someone I have HIV is risky

0.51
0.63

STIGMA

People with HIV are treated like outcasts

0.68

Most people believe that a person who is
HIV is dirty

0.59
0.63

Most people are uncomfortable around
someone with HIV

0.65
0.66

I feel guilty because I have HIV
Peoples attitudes about HIV make me feel
worse about myself
I feel I am not as good as others because I
have HIV

Fig. 2 Confirmatory factor analysis of the unidimensional HSS-10. Sample (n = 195). Maximum likelihood estimates are standardised

Analyses of the HSS‑10 item abridged scale
Internal consistency

Factor structure and measurement model by gender and age
sub‑groups

The HSS-10 had an internal consistency reliability coefficient alpha = 0.86 (95% CI 0.84–0.89) (see Table 3).
The corrected item-total correlation coefficient ranged
between 0.51 and 0.68, indicating that the intended
stigma concept’s broadness had been captured.

Confirmatory Factor Analysis tested the unidimensional
HSS-10 model. The χ2 test was statistically insignificant
(χ2 = 46.183, df = 35, p = 0.098). Additionally, other model

Table 3 Descriptive statistics for items in the abridged version (hss-10) of the hiv stigma scale
Item

Median
item scorea
(iqr)

Corrected
item
correlation

Total score
[median
(iqr)]

Reliability

Construct
α

Some people stop touching me soon they know/
realise I am infected with HIV/AIDS

1 (0–2)

0.60

People I care for stopped calling me after knowing I
suffer from AIDs

1 (0–2)

0.63

I have lost friends for telling/explaining that I have
AIDS

1 (0–2)

0.59

Telling someone that I have AIDS is dangerous*

1 (0–2)

0.51

People who are suffering from AIDS are treated as if
they are not like the other people

1 (0–2)

0.63

People believe that a person infected with HIV is dirty 1 (0–2)

0.68

Many people are worried when they are near a person infected with HIV

1 (0–2)

0.59

I feel guilty because I am infected with HIV

1 (0–2)

0.63

People’s attitudes about HIV/AIDS makes me feel very 1 (1–2)
bad

0.65

I feel I am not as good as others because am infected
with HIV

0.66

1 (0–2)

Overall
IQR interquartile Range
a

Possible score for each item 1–4; higher scores reflect a higher level of perceived HIV stigma

11 (7–16)

Validity

CFI

RMSEA TLI

0.86 (95% CI; 0.84–0.89) 0.976 0.040

0.969

Wanjala et al. Global Health Research and Policy

(2021) 6:49

Page 7 of 10

fit indices indicated that our data fit the unidimensional
model (RMSEA: 0.040; TLI: 0.969; CFI: 0.976).
Subsequently, four multi-Group Confirmatory Factor
Analyses (MGCFA) were conducted separately for both
sex and age sub-groups. All the models exhibited a good
fit based on the CFI being greater than 0.90 (see Table 4).
Furthermore, model fit based on RMSEA was best in
the strict invariance model for both sex [RMSEA: 0.013
(90% CI 0.000–0.055)] and age [RMSEA: 0.037 (90% CI
0.000–0.067)], suggesting that constraining factor loadings, intercepts and variances improved model fit in the
strict factorial invariance model compared to the configural, metric and scalar invariance models (see Table 4 for
the details of the invariance results).

Discussion
Our study aimed to examine the psychometric properties
of a short version of the HSS-40 [18], translated into Swahili using baseline data from a longitudinal study among
perinatally HIV-infected adolescents. We evaluated the
HSS-12 [20] reliability and construct validity, which indicated insufficient reliability on three of the four subscales.
Especially concerning was the extremely poor reliability
of the disclosure concern subscale. Accordingly, we conducted an exploratory factor analysis to improve scale
structure. Our results indicated the need to exclude two
items and create an abridged version of the scale (HSS10). The EFA supported the scale’s construct validity and
resulted in a unidimensional 10-item scale measuring the
construct stigma.
Reliability and construct validity of the Swahili HSS‑10

Two items from the disclosure concerns subscale with
factor loadings < 0.4 were dropped, consequently improving the scale reliability. The Swahili version of the HSS10 demonstrated adequate internal consistency reliability

suggesting that the ten items in the questionnaire reflect
the latent construct of HIV stigma. However, the two
items could have had poor loading for various reasons.
Firstly, the translation may have been inadequate, thus
raising ambiguity. However, a robust approach was used
to develop these translations and back translations; the
exact translation has shown adequate reliability among
adults [43]. Secondly, potentially, the two items were
not developmentally appropriate for adolescents. Therefore, we recommend future studies to investigate why
the two items had low factor loadings when used among
adolescents.
Factor structure and measurement model

Berger’s HIV stigma scale (HSS-40) [19] measures four
dimensions of stigma: personalised stigma, disclosure
concerns, concerns with public attitudes, and negative
self-image. The initial version of the present study’s questionnaire contained twelve items (HSS-12) covering all
the four domains. However, the poor psychometric properties of two items measuring disclosure concerns subscale led to a reduction of the initial 12–item scale into
the final 10-item unidimensional HIV stigma scale. The
scale’s unidimensional structure is supported by high
alphas and the large ratio of the 1st/2nd eigenvalues.
This unidimensional structure confirms that the HSS-10
assesses a single underlying factor (HIV stigma) among
our study population. This finding corroborates what has
been reported in other studies. For instance, despite four
factors emerging after EFA in the USA, extraction of one
higher-order factor provided evidence of a single overall
construct [19].
Additionally, we found that the one-factor solution
explained 39% of the variance. However, HIV stigma
is a multi-dimensional construct [20, 21, 24] that differs across cultures [21]. Therefore, the difference in the

Table 4 Multi-group confirmatory factor analysis for age and gender sub-groups
Group
Age

Sex

Invariance

χ2 (df)

p value

CFIb

TLIb

RMSEAb

Δχ2 (Δdf)

Configural

80.86 (70)

0.176

0.974

0.967

0.040 [0.000–0.074]

–

Metric/weak

92.89 (79)

0.136

0.967

0.962

0.042 [0.000–0.074]

10.98 (9)

p valuea
–
0.2774

ΔCFI
0.007
0.001

ΔRMSEA
–
0.002

Scalar/strong

101.34 (88)

0.157

0.968

0.967

0.039 [0.000–0.070]

8.77 (9)

0.4583

0.001

0.003

Strict

111.06 (98)

0.173

0.969

0.971

0.037 [0.000–0.067]

10.60 (10)

0.3897

0.001

0.002

Configural

91.84 (88)

0.369

0.992

0.992

0.021 [0.000–0.060]

–

Metric/weak

82.13 (79)

0.383

0.993

0.992

0.020 [0.000–0.061]

10.06 (9)

–
0.3452

0.001
0.001

–
0.001

Scalar/strong

91.76 (88)

0.371

0.992

0.992

0.021 [0.000–0.060]

9.79 (9)

0.3681

0.001

0.001

Strict

99.60 (98)

0.436

0.997

0.997

0.013 [0.000–0.055]

8.20 (10)

0.6094

0.005

0.008

a

The chi-square difference value is not significant. It indicated that constraining the parameters of the nested model did not significantly worsen the fit of the model.
Our result indicated measurement invariance

b

Criteria for an acceptable fit were a root mean square error of approximation of < 0.06, and a comparative fit index (CFI) and a Tucker-Lewis index (TLI) of ≥ 0.90.
Configural invariance—no constraints; Full metric invariance—with all factor loadings constrained equal. Scalar invariance—with all intercepts constrained equal;
Strict invariance—with all factor loadings and intercepts fixed; Measurement invariance is assumed when ΔCFI is ≤ 0.01
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scale’s structure might be due to how different populations and cultures conceptualise HIV stigma or that adolescents might not conceptualise stigma as adults do.
Measurement invariance test

Our results support the presence of a strict invariance
according to age and sex, allowing meaningful group
comparisons among perinatally HIV-infected adolescents
at the Kenyan Coast. Therefore, we can confidently compare means and conclude that any difference between the
unidimensional HSS-10 across sex and age groups comes
from a real difference in HIV stigma and not from the
measure’s group-specific properties. Although various
studies have used the 40–item HIV stigma scale [19] and
the 12-item HIV stigma scale [20, 44] to assess stigma
and reported their psychometric properties, no study
has been found to report the measurement invariance of
the tool. Therefore, future research involving HIV stigma
assessment tools should use robust psychometric analytical models involving measurement invariance.
Relevance in public health

Although several stigma scales exist, Berger et al.’s [19]
40-item HIV stigma scale is the most commonly used
around the world that covers all stigma mechanisms
affecting people [6]. Additionally, it presents solid evidence of validity and reliability [19]. However, to be
included in more extensive surveys, a shorter instrument
is preferred [20]. Improved brevity means that this tool
may have beneficial clinical implications if included in
routine care. It is less labour intensive yet can screen for
a problem that significantly impedes HIV care and treatment. Our results support the use of the Swahili version
of the HSS-10 among the Kenyan adolescent population.
The evidence suggests the possibility of using HSS-10
among adolescents in other Swahili-speaking countries.
Additionally, further adaptations could be made to the
HSS-12 to understand why the two items failed, conducting cognitive interviews with adolescents to fully
understand what else could be measured to capture their
stigma experiences fully.
Strengths and limitations of this study

The study’s strength is that it focused on the adolescent
sub-population, which is rarely an area of focus. Moreover, we used robust psychometric analytical models that
involve measurement invariance, an important aspect of
structural validity. However, several limitations of this
study must be considered when interpreting the findings and should be addressed in future studies. First, our
results are based on a sample of perinatally HIV-infected
adolescents attending a specialised HIV clinic in a rural
context and who have already undergone the entire
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disclosure process. This might limit the generalizability of these findings to adolescents from urban settings
who either attend a private hospital or have not undergone the full disclosure process and who have acquired
HIV behaviorally. Secondly, we did not investigate various aspects of scale reliability (e.g., test–retest reliability
of the Swahili version of the HSS-10 to ascertain scale
stability over time). Future studies should explore the
test–retest and inter-rater reliability of the HSS-10 when
used among adolescents to ascertain scale stability over
time. However, it is unlikely that the absence of test–
retest reliability and inter-rater reliability in the present
study had any major issues given that proper translation
procedures of the HSS-10 to Swahili were observed and
cognitive interviews from tool adaptation revealed that
participants well comprehended the items of the Swahili version of HSS-10. Third, we did not examine invariance based on certain socio-economic measures such
as household income because the study population is
very homogenous, so there may be little differentiation
to make. Future studies should investigate the potential
implication of such factors on measurement invariance
since socio-economic factors may influence HIV stigma.
Lastly, we did not test for discriminant validity as we only
collected data for the HIV stigma scale. Future research
should consider assessing discriminant validity.

Conclusion
This study presents a first published assessment of the
HSS-12 in the adolescent population from East Africa.
Evidence presented supports a unidimensional model
and measurement invariance of the HSS-10 allowing
for reliable comparisons between sex and age groups.
Besides, measurement invariance is unlikely to be
affected by differences in time-lapse, response styles,
socio-economic factors, and interpretations of indicators. Furthermore, based on its validity and reliability,
the HSS-10 is recommended as a useful tool for measuring HIV stigma among perinatally HIV-infected adolescents. Adolescents from the Kenyan coast appear to
be experiencing stigma related to disclosure concerns
than in the domains of personalised stigma, negative
self-image, and concerns with public attitudes. Further
research is needed to determine whether the psychometric soundness of the HSS-10 reported here would
hold among perinatally HIV-infected adolescents from
other regions for both females and males of different
age groups and socio-economic status. Lastly, as this
is the first study using the HSS-10, validation of this
measure is vital in evaluating interventions to scale
down HIV stigma in addition to its practical implication for future stigma research.
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